Aurobindo Pharma.
an Indian pharmaceutical company
- Reports this week
- 3
- Active events
- 1
- Connections
- 42
What's happening
Active this week
Earlier this month
One to three months ago
-
The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.Well supported7 reports5 developments inside
-
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, faces regulatory issues in the US market.Some support4 reports
-
Market updates regarding Hindalco Industries, SIS, Aurobindo Pharma, and Bayer CropScience were reported in Mumbai starting August 1, 2026.Some support1 report1 development inside
-
SBI Securities predicts a bullish technical breakout for Aurobindo Pharma and Union Bank of India.Some support1 report
-
Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.Some support1 report
-
US-Iran tensions drive up oil prices, widening India's import bill and affecting various sectors like pharmaceuticals.Well supported16 reports4 developments inside
-
Trump announced plans for tariffs on generic drug imports while crude oil prices surged.Some support8 reports
-
Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.Well supported13 reports2 developments inside
-
Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.Some support11 reports
-
Maruti Suzuki and Aurobindo Pharma face price hikes due to input costs, while Aurobindo establishes a biosimilars facility in Hyderabad and receives ANVISA approval.Some support1 report
-
A fund increased its conviction in both Tata Communications and Aurobindo Pharma stocks on July 8, 2026.Some support1 report
-
Stocks across various sectors are showing strong buying interest and hitting 52-week highs, reflecting positive domestic market trends.Some support2 reports
-
Multiple corporate actions, including a settlement with NMC Health PLC, fintech partnerships with Canara Bank, and battery cell agreements.Some support1 report
-
Aurobindo Pharma, Zensar Technologies, Torrent Pharmaceuticals, and Aadhar Housing Finance showed strong upward momentum on July 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Aurobindo Pharma is experiencing targets suggesting significant revenue growth and market expansion.Some support2 reports
-
A market report lists several Indian companies, including Maruti Suzuki and Aurobindo Pharma, as laggards or movers following a global oil price drop.Some support2 reports
-
Aurobindo Pharma, which has a facility in Telangana, owns Eugia Pharma Specialities.Some support1 report
-
Solar projects are being secured under state government schemes, while an Iran-US agreement boosts investor sentiment in India. Meanwhile, an Indian pharma company faces USFDA inspection issues.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Aurobindo Pharma this week
News at the entities that move Aurobindo Pharma most-
Brent OperationalECB chair signals readiness to raise rates as potential attacks in Yemen drive oil price spikes and market risk-off.Moves Aurobindo Pharma
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Aurobindo Pharma
-
European Medicines Agency StructuralBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves Aurobindo Pharma
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Aurobindo Pharma
-
United States Food and Drug Administration StructuralFDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Moves Aurobindo Pharma
-
Europe StructuralThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Aurobindo Pharma
Connections
The 23 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Donald Trump Operational
Trump's proposed tariff policies are actively pressuring Aurobindo Pharma's market viability and generic drug imports.
-
FDA Structural
Aurobindo Pharma is currently undergoing inspections by the FDA regarding manufacturing compliance.
-
United States Food and Drug Administration Structural
US FDA conducts inspections of Aurobindo Pharma subsidiaries as part of regulatory oversight.
-
Brent Operational
Brent crude oil price movements contribute to market uncertainty, which subsequently affects the sentiment and operational costs of pharmaceutical companies like Aurobindo.
-
Europe Structural
The European market provides necessary conditions and revenue support for Aurobindo Pharma's operations.
-
Cipla Operational
The two companies are direct competitors facing shared market pressure due to US tariffs.
-
Telangana Structural
Aurobindo Pharma operates a facility in Telangana, which is subject to state regulations and international oversight.
-
Bajaj Life Insurance Operational
The available evidence suggests the two companies are actively interacting in the market, though specific details are missing.
Show all 23 connections
-
MSD Transactional
MSD and Aurobindo Pharma entered a voluntary licensing agreement for the generic drug alimatravir.
-
India Shared context
Aurobindo Pharma operates as a company within the Indian market structure.
-
European Medicines Agency Structural
The European Medicines Agency has certified a facility belonging to Aurobindo Pharma.
-
Hyderabad Shared context
Aurobindo Pharma operates its biosimilars manufacturing facility and headquarters within the geographical boundaries of Hyderabad.
-
Federal Bank Mentioned together
Both companies were mentioned in the context of stocks registering fresh life-time highs in August 2026.
-
Tata Communications Mentioned together
Both stocks are noted by a fund for increased conviction.
-
Acadia Pharmaceuticals Operational
Acadia Pharmaceuticals and Aurobindo Pharma are engaged in legal competition regarding intellectual property rights.
-
Kalyan Jewellers Mentioned together
The entities are co-mentioned as midcap movers in the market.
-
Raleigh Shared context
Aurobindo Pharma operates a plant in Raleigh that is undergoing regulatory review.
-
Zensar Technologies Mentioned together
The entities were co-mentioned in articles noting they both experienced strong upward market momentum.
-
Mumbai Shared context
The company is mentioned in market updates related to the city's operational context.
-
SBI Securities Mentioned together
Both SBI Securities and Aurobindo Pharma are currently trading at record levels with strong market momentum.
-
Macquarie Transactional
Macquarie initiated a Neutral rating on Aurobindo Pharma.
-
CSR Transactional
The two entities engaged in a charitable transaction, donating Rs 10 crore towards school meals.
-
Federal Trade Commission Mentioned together
No evidence was provided linking Aurobindo Pharma and the Federal Trade Commission.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
4 events- Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, faces regulatory issues in the US market.
- Market updates regarding Hindalco Industries, SIS, Aurobindo Pharma, and Bayer CropScience were reported in Mumbai starting August 1, 2026.
- SBI Securities predicts a bullish technical breakout for Aurobindo Pharma and Union Bank of India.
- Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.
July 2026
10 events- MSD and Aurobindo Pharma signed a voluntary licensing agreement for generic alimatravir.
- US-Iran tensions drive up oil prices, widening India's import bill and affecting various sectors like pharmaceuticals.
- Trump announced plans for tariffs on generic drug imports while crude oil prices surged.
- Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.
- Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.
- Maruti Suzuki and Aurobindo Pharma face price hikes due to input costs, while Aurobindo establishes a biosimilars facility in Hyderabad and receives ANVISA approval.
- A fund increased its conviction in both Tata Communications and Aurobindo Pharma stocks on July 8, 2026.
- Stocks across various sectors are showing strong buying interest and hitting 52-week highs, reflecting positive domestic market trends.
- Multiple corporate actions, including a settlement with NMC Health PLC, fintech partnerships with Canara Bank, and battery cell agreements.
- Aurobindo Pharma, Zensar Technologies, Torrent Pharmaceuticals, and Aadhar Housing Finance showed strong upward momentum on July 1, 2026.
Show 1 earlier month
June 2026
5 events- The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.
- Aurobindo Pharma is experiencing targets suggesting significant revenue growth and market expansion.
- A market report lists several Indian companies, including Maruti Suzuki and Aurobindo Pharma, as laggards or movers following a global oil price drop.
- Aurobindo Pharma, which has a facility in Telangana, owns Eugia Pharma Specialities.
- Solar projects are being secured under state government schemes, while an Iran-US agreement boosts investor sentiment in India. Meanwhile, an Indian pharma company faces USFDA inspection issues.